Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?
- PMID: 10064238
- DOI: 10.1086/515126
Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?
Abstract
Solid organ transplant recipients are at risk for Pneumocystis carinii pneumonia (PCP), but the risk of PCP beyond 1 year is poorly defined. We identified 25 cases of PCP in 1,299 patients undergoing solid organ transplantation between 1987 and 1996 at The Cleveland Clinic Foundation (4.8 cases per 1,000 person transplant-years [PTY]). Ten (36%) of 28 PCP cases (transplantation was performed before 1987 in three cases) occurred > or = 1 year after transplantation, and no patient developed PCP while receiving prophylaxis for PCP. The incidence of PCP during the first year following transplantation was eight times higher than that during subsequent years. The highest rate occurred among lung transplant recipients (22 cases per 1,000 PTY), for whom the incidence did not decline beyond the first year of transplantation. We conclude that the incidence of PCP is highest during the first year after transplantation and differs by type of solid organ transplant. Extending the duration of PCP prophylaxis beyond 1 year may be warranted for lung transplant recipients.
Comment in
-
Editorial response: Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients--as long as the pros outweigh the cons.Clin Infect Dis. 1999 Feb;28(2):247-9. doi: 10.1086/515127. Clin Infect Dis. 1999. PMID: 10064239 No abstract available.
Similar articles
-
Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.Transpl Infect Dis. 2012 Oct;14(5):519-25. doi: 10.1111/j.1399-3062.2012.00740.x. Epub 2012 May 10. Transpl Infect Dis. 2012. PMID: 22571389
-
A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.Bone Marrow Transplant. 1999 Oct;24(8):897-902. doi: 10.1038/sj.bmt.1702004. Bone Marrow Transplant. 1999. PMID: 10516703 Clinical Trial.
-
Pneumocystis carinii pneumonia in renal transplant recipients.Nephrol Dial Transplant. 1995;10(7):1194-7. Nephrol Dial Transplant. 1995. PMID: 7478123
-
Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation.Bone Marrow Transplant. 1997 Nov;20(10):879-81. doi: 10.1038/sj.bmt.1700978. Bone Marrow Transplant. 1997. PMID: 9404930 Review.
-
Pneumocystis jirovecii pneumonia in kidney transplantation.Transpl Infect Dis. 2011 Dec;13(6):551-8. doi: 10.1111/j.1399-3062.2011.00691.x. Epub 2011 Oct 31. Transpl Infect Dis. 2011. PMID: 22093172 Review.
Cited by
-
Selection of Pneumocystis jirovecii Inosine 5'-Monophosphate Dehydrogenase Mutants in Solid Organ Transplant Recipients: Implication of Mycophenolic Acid.J Fungi (Basel). 2021 Oct 10;7(10):849. doi: 10.3390/jof7100849. J Fungi (Basel). 2021. PMID: 34682270 Free PMC article.
-
m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2019 Nov;75(11):1471-1480. doi: 10.1007/s00228-019-02730-0. Epub 2019 Aug 3. Eur J Clin Pharmacol. 2019. PMID: 31377892
-
Critical Care after Lung Transplantation.Acute Crit Care. 2018 Nov;33(4):206-215. doi: 10.4266/acc.2018.00360. Epub 2018 Nov 30. Acute Crit Care. 2018. PMID: 31723887 Free PMC article. Review.
-
Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.J Fungi (Basel). 2015 Sep 28;1(3):293-331. doi: 10.3390/jof1030293. J Fungi (Basel). 2015. PMID: 29376913 Free PMC article. Review.
-
Lung transplant infection.Respirology. 2013 Jan;18(1):22-38. doi: 10.1111/j.1440-1843.2012.02196.x. Respirology. 2013. PMID: 22591266 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical